Newsbenzinga
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study
· Published
Article summary
AstraZeneca and Amgen report positive Phase 3 Tezspire data, showing sustained remission in eosinophilic esophagitis patients over 52 weeks.
An excerpt from the original article.
Comments —
Loading comments…